Weekly Investment Analysts’ Ratings Changes for PTC Therapeutics (PTCT)

by · The Cerbat Gem

Several brokerages have updated their recommendations and price targets on shares of PTC Therapeutics (NASDAQ: PTCT) in the last few weeks:

  • 11/2/2026 – PTC Therapeutics had its price target raised by Citigroup from $108.00 to $109.00. They now have a “buy” rating on the stock.
  • 10/31/2026 – PTC Therapeutics was downgraded by Wall Street Zen from “buy” to “hold”.
  • 10/30/2026 – PTC Therapeutics had its price target raised by TD Cowen from $90.00 to $95.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – PTC Therapeutics had its price target raised by Wells Fargo & Company from $109.00 to $112.00. They now have an “overweight” rating on the stock.
  • 10/30/2026 – PTC Therapeutics had its price target raised by Royal Bank Of Canada from $75.00 to $77.00. They now have a “sector perform” rating on the stock.
  • 10/20/2026 – PTC Therapeutics was given a new $106.00 price target by Raymond James Financial.
  • 10/16/2026 – PTC Therapeutics is now covered by Truist Financial. They set a “hold” rating and a $62.00 price target on the stock.
  • 10/15/2026 – PTC Therapeutics is now covered by UBS Group. They set a “buy” rating and a $90.00 price target on the stock.
  • 10/14/2026 – PTC Therapeutics was upgraded by UBS Group to “strong-buy”.
  • 10/10/2026 – PTC Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 10/8/2026 – PTC Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
  • 10/7/2026 – PTC Therapeutics had its price target lowered by Royal Bank Of Canada from $85.00 to $75.00. They now have a “sector perform” rating on the stock.
  • 9/22/2026 – PTC Therapeutics had its price target raised by Cantor Fitzgerald from $130.00 to $137.00. They now have an “overweight” rating on the stock.
  • 9/19/2026 – PTC Therapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 9/17/2026 – PTC Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
  • 9/14/2026 – PTC Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $98.00 price target on the stock.

Insider Activity

In other PTC Therapeutics news, Director Michael Schmertzler sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $72.94, for a total value of $911,750.00. Following the sale, the director owned 1,349,094 shares of the company’s stock, valued at $98,402,916.36. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Klein sold 10,292 shares of PTC Therapeutics stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $68.57, for a total value of $705,722.44. Following the sale, the chief executive officer owned 383,868 shares of the company’s stock, valued at approximately $26,321,828.76. This trade represents a 2.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 77,370 shares of company stock worth $5,322,261. Company insiders own 5.30% of the company’s stock.

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.

Read More